Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-29

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will identify the sex-dependent impact of expiratory-gated transcutaneous vagus nerve stimulation (tVNS) on the modulation of the stress response circuitry and associated physiology in major depressive disorder (MDD). We will evaluate a sample of 80 adults with recurrent MDD randomized to receive active or sham expiratory-gated tVNS during a functional magnetic resonance imaging (fMRI) session, with simultaneous mood and physiological assessments. We hypothesize that expiratory-gated tVNS will effectively modulate, in a sex-dependent manner, specific brainstem-cortical pathways of the stress circuitry and attenuate physiological deficits in MDD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

tVNS for Depression

NCT02562703

Depressive Disorder

UNKNOWN PHASE1/PHASE2

Non-invasive Vagus Nerve Stimulation as a Tool to Modulate Stomach-Brain Coupling in Depression

NCT06389175

Depressive Disorder, Major

ENROLLING_BY_INVITATION NA

tVNS Effects on Motivation in Depression

NCT05120336

Major Depressive Disorder

COMPLETED NA

Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses

NCT00305565

Depression

COMPLETED PHASE4

taVNS or TMS or Both for Depression

NCT05725239

Depression

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Major depressive disorder (MDD) is a leading cause of morbidity and disability worldwide with abnormalities in the stress response circuitry and central autonomic network. Many of these regions are sexually dimorphic and related with sex differences in mood and hypothalamic-pituitary-adrenal (HPA) axis modulation, the dysregulation of which is associated with alterations of hormone and immune responses to stress, autonomic dysfunction and increased cardiovascular risk. The primary goal of this study is to use non-invasive neuromodulatory stimulation of the vagus to target the circuitry associated with stress-immune function and map its neuroanatomic and physiological effects in MDD by sex. Vagal nerve stimulation (VNS), FDA-approved for MDD, modulates brain circuitry implicated in mood/anxiety and autonomic regulation, however, it is implanted and thus invasive. We propose the use of a physiologically-enhanced transcutaneous VNS (tVNS) as a low risk, non-invasive, and inexpensive alternative. While tVNS has had beneficial effects on depressive symptomatology and autonomic regulation, current stimulation parameters are based on historical iVNS data that included mostly male populations. We propose that tVNS effects on the regulation of specific brainstem-cortical pathways is modulated by sex. Moreover, as the dorsal medullary vagal system operates in tune with respiration, we recently demonstrated that tVNS can be optimized by gating stimulation to respiration. Thus, this study proposes to identify the sex-dependent impact of expiratory-gated tVNS on the modulation of stress response circuitry alterations and physiological dysregulation of recurrent MDD. We will evaluate a sample of 80 adults with recurrent MDD randomized to receive active tVNS or sham stimulation during a functional magnetic resonance imaging (fMRI) session. The fMRI session will include a stress challenge designed to elicit a sympatho-excitatory state, with simultaneous mood and physiological assessments, including hormonal and dynamic cardiovagal heart rate variability (HRV) evaluations. We hypothesize that expiratory-gated tVNS will effectively modulate specific brainstem-cortical pathways of the stress response circuitry and will attenuate physiological deficits of recurrent MDD patients. We further hypothesize that tVNS will impact brain activity and physiology in sex-dependent ways.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active tVNS

Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle

Group Type EXPERIMENTAL

active tVNS

Intervention Type DEVICE

non-painful electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session

Sham tVNS

Sham transcutaneous vagus nerve stimulation on the left auricle

Group Type SHAM_COMPARATOR

Sham tVNS

Intervention Type DEVICE

Sham stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

active tVNS

non-painful electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session

Intervention Type DEVICE

Sham tVNS

Sham stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

transcutaneous vagus nerve stimulation transcutaneous vagus nerve stimulation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Current or past diagnosis of recurrent Major Depressive Disorder

Exclusion Criteria

* History of neuroleptic use
* Any psychiatric disorder involving a history of psychosis (e.g. schizophrenia, bipolar I disorder)
* Active suicidal ideation with intent and/or plan or history of a suicide attempt within the last year
* Moderate or severe substance use disorder within the past 12 months
* Diagnosis of significant cardiovascular or cerebrovascular disease (e.g. congestive heart failure, stroke, cardiac conduction disorders, history of asystole or non-sustained ventricular tachycardia)
* Diseases affecting the CNS (e.g. MS, epilepsy, neurodegenerative diseases, etc.)
* Traumatic brain injury with cognitive sequelae
* MRI or tVNS contraindications (e.g. claustrophobia, metallic implants or devices)
* Pregnancy (uncommon, given the age of this cohort is 50+ years) due to unknown health risks for the fetus

Minimum Eligible Age

50 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No